Novel opportunity of treatment for psycho-cardiologic disease by gut microbiome

Area of Science:

• Integrative medicine
• Microbiome research
• Psychocardiology

Background:

• Comorbidity of cardiovascular disease (CVD) with psychiatric disorders like depression and anxiety is increasing.
• Patients with comorbid CVD and psychiatric disorders exhibit poorer health outcomes.
• Gut microbiota dysbiosis and altered metabolite profiles are implicated as risk factors for both CVD and psychosomatic disorders.

Purpose of the Study:

• To review the mechanisms linking gut microbiota and its metabolites to psychocardiologic diseases.
• To summarize the therapeutic potential of gut microbiota interventions in managing these conditions.
• To highlight new research directions for treating psychocardiologic diseases.

Main Methods:

• Literature review of studies on gut microbiota, metabolites, CVD, and psychiatric disorders.
• Analysis of mechanisms connecting gut dysbiosis to psychocardiologic pathophysiology.
• Evaluation of evidence for gut microbiota-targeted therapies.

Main Results:

• Gut microbiota dysbiosis and specific metabolite alterations are significant risk factors for psychocardiologic diseases.
• These microbial changes contribute to the pathophysiology of both cardiovascular and psychiatric conditions.
• Gut microbiota interventions show promise as a therapeutic strategy.

Conclusions:

• The gut microbiota plays a crucial role in the development and progression of psychocardiologic diseases.
• Targeting the gut microbiota offers a novel therapeutic avenue for patients with comorbid CVD and psychiatric disorders.
• Further research into microbiota-based interventions is warranted to improve patient prognosis.